Largest biotech companies by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 24 biotech companies ranked by net assets, at NOK 219.9B, ahead of BioNTech (NOK 206.6B) and Biogen (NOK 176.9B). Figures as of 18 Nov 2026, 18:28 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesNOK 219.9B
- Median
- NOK 19.5B
- Combined market value
- NOK 8.15T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | NOK 219.9B | NOK 2.03T | NOK 1,638.87 | 0.63% down | 33% up | ||
| 2 | BioNTechBNTX · Health Care | NOK 206.6B | NOK 201.7B | NOK 813.41 | 1.05% down | 16% down | ||
| 3 | BiogenBIIB · Health Care | NOK 176.9B | NOK 361.2B | NOK 2,443.51 | 0.58% up | 49% up | ||
| 4 | AmgenAMGN · Health Care | NOK 83.9B | NOK 2.34T | NOK 4,326.98 | 2.46% down | 34% up | ||
| 5 | ModernaMRNA · Health Care | NOK 83.8B | NOK 786.6B | NOK 1,944.13 | 2.95% down | 755% up | ||
| 6 | argenxARGX · Health Care | NOK 70.9B | NOK 577.2B | NOK 9,178.20 | 0.00% down | 4% up | ||
| 7 | QiagenQGEN · Health Care | NOK 36.6B | NOK 99.4B | NOK 481.34 | 0.12% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | NOK 31.5B | NOK 160.5B | NOK 1,585.55 | 1.35% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | NOK 26B | NOK 90.2B | NOK 569.78 | 0.98% down | 22% up | ||
| 10 | ExelixisEXEL · Health Care | NOK 20.9B | NOK 163.2B | NOK 668.68 | 0.77% up | 63% up | ||
| 11 | Bio-TechneTECH · Health Care | NOK 20.4B | NOK 110.8B | NOK 705.25 | 0.24% up | 26% up | ||
| 12 | RepligenRGEN · Health Care | NOK 20.4B | NOK 107.4B | NOK 1,680.28 | 6.96% up | 5% up | ||
| 13 | CRISPR TherapeuticsCRSP · Health Care | NOK 18.6B | NOK 39B | NOK 402.34 | 3.45% up | 21% down | ||
| 14 | Revolution MedicinesRVMD · Health Care | NOK 15.8B | NOK 337.2B | NOK 1,558.86 | 1.08% down | 131% up | ||
| 15 | Kymera TherapeuticsKYMR · Health Care | NOK 15.3B | NOK 101B | NOK 1,183.54 | 0.54% up | 87% up | ||
| 16 | Krystal BiotechKRYS · Health Care | NOK 11.8B | NOK 89.9B | NOK 3,034.07 | 4.91% up | 46% up | ||
| 17 | ImmunovantIMVT · Health Care | NOK 8.3B | NOK 67.1B | NOK 324.03 | 0.72% up | 43% up | ||
| 18 | CG OncologyCGON · Health Care | NOK 7.3B | NOK 70.3B | NOK 786.86 | 2.90% up | 85% up | ||
| 19 | Twist BioscienceTWST · Health Care | NOK 4.6B | NOK 78B | NOK 1,143.53 | 5.40% up | 340% up | ||
| 20 | Scholar Rock HoldingSRRK · Health Care | NOK 2.4B | NOK 56.3B | NOK 461.72 | 5.73% up | 14% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | NOK 2.1B | NOK 45.1B | NOK 278.88 | 1.05% up | 88% up | ||
| 22 | Kodiak SciencesKOD · Health Care | NOK 1.5B | NOK 61.3B | NOK 937.69 | 0.00% | 396% up | ||
| 23 | Halozyme TherapeuticsHALO · Health Care | NOK 472.9M | NOK 106.5B | NOK 934.30 | 0.50% up | 37% up | ||
| 24 | ImmunityBioIBRX · Health Care | -NOK 4.8B | NOK 69B | NOK 64.90 | 7.03% up | 193% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6869 NOK).
Questions and answers
Which biotech companies rank first by net assets?
Gilead Sciences (NOK 219.9B), BioNTech (NOK 206.6B) and Biogen (NOK 176.9B) are the top three of the 24 biotech companies ranked by net assets as of 18 Nov 2026, 18:28 UTC.
How many biotech companies are in this ranking?
24 are ranked by net assets.
What are these biotech companies worth together?
The 24 biotech companies ranked by net assets have a combined market value of NOK 8.15T as of 18 Nov 2026, 18:28 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.